PKIG

Across TCGA pan-cancer cohorts, PKIG mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PKIG data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PKIG mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PKIG expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where PKIG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.881	0.346	.003	38	view →
LSCC	DFS	Median	II,III,IV	0.535	0.858	.007	34	view →
CCRCC	DFS	Median	III,IV	0.960	0.766	.013	11	view →
COAD	DFS	Median	III,IV	0.742	1.000	.036	6	view →
LUAD	DFS	Median	All	0.754	0.506	.012	6	view →
GBM	DFS	Quartile	All	0.923	0.700	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PKIG–PDAC (OS)

Open the PDAC breakdown →